Abpro announced a partnership with Essex Bio. Abpro and Essex will co-develop multiple monoclonal antibodies in immuno-oncology and ophthalmology by leveraging Abpro's DiversImmune platform. Abpro received a $3.5 million equity investment from Essex Bio and an undisclosed amount from affiliates, as part of the agreement.

According to the agreement, Abpro will receive an upfront equity investment from Essex Bio and affiliates. The companies will advance multiple assets through pre-clinical and clinical development and seek commercial authorizations. Essex Bio holds commercial rights to these assets in China, and Abpro retains commercialization rights in the U.S. and rest of world, excluding China, with cross-royalties from each region.

Through its DiversImmune platform, Abpro generates antibodies with high sensitivity and specificity for advancing human health.